real peptides FAQ

Time kisspeptin administration to the estrous or menstrual cycle phase. Kisspeptin neuron activity is sexually dimorphic and cycle-dependent. AVPV kisspeptin neurons drive the preovulatory LH surge in females, while arcuate nucleus kisspeptin neurons regulate basal pulsatile secretion. Estradiol exerts positive feedback on AVPV kisspeptin expression during the late follicular phase, amplifying the GnRH/LH surge. Administering kisspeptin during the luteal phase (high progesterone) produces smaller LH responses than during the follicular phase. Researchers studying ovulation induction or surge mechanisms should administer kisspeptin during proestrus (rodents) or the late follicular phase (primates) to maximize physiological relevance.

Discard all reconstituted peptide solutions immediately. Temperature excursions above 8°C for more than 4 hours cause irreversible structural changes that laboratory testing cannot reliably detect. For unreconstituted lyophilised powder, the decision depends on duration: Cartalax powder tolerates up to 24 hours at room temperature with minimal loss, but Thymalin's polypeptide structure begins degrading after 6–8 hours at 20–25°C. The financial cost of discarding potentially compromised peptides is negligible compared to three months of experimental data generated with degraded compounds. We've consulted on cases where researchers spent 12 weeks troubleshooting protocols. Only to discover the peptide had been compromised during a single overnight refrigeration failure.

Reduce the dose by 40–50% and extend the interval between administrations from daily to every 48–72 hours. Persistent headache-like behavior beyond the acute adaptation period suggests the rate of synaptogenesis exceeds the capacity of glial support cells to regulate extracellular glutamate and maintain ionic homeostasis. Reducing dose and frequency allows neural plasticity to continue while giving homeostatic mechanisms time to adapt. If behavioral indicators persist beyond 7 days at reduced dose, discontinue administration and allow a 14-day washout before resuming at a lower starting dose.

Refrigerate immediately and discard if room temperature exposure exceeded 8 hours. Peptide bond hydrolysis accelerates exponentially above 15°C. A single overnight excursion (8–12 hours at 20–22°C) produces 10–15% potency loss, introducing systematic dosing error across remaining research uses. The solution may appear unchanged because peptide fragments remain in solution, but HPLC analysis would reveal multiple degradation peaks indicating fragmented sequences. Attempting to continue using temperature-compromised solution means your late-study doses contain fundamentally different peptide populations than early-study doses, confounding longitudinal data interpretation with a chemical variable rather than a biological response.

Verify amino acid sequence through mass spectrometry before attributing inconsistency to protocol variables. The Cartalax vs Thymalin comparison relies on exact peptide sequences. But commercial suppliers frequently substitute similar sequences or provide peptide mixtures without disclosure. Cartalax must contain the specific Ala-Glu-Asp-Gly sequence; variations like Lys-Glu-Asp-Gly produce different receptor binding profiles entirely. Thymalin's complexity introduces additional variables. Extraction methods and purification protocols affect which polypeptide fractions dominate the final product. Real Peptides performs small-batch synthesis with sequence verification on every lot, but third-party materials should be independently validated.

Immediate protocol modification is required. Implement a 5–7 day washout period with no dihexa administration. Anxiety-like behavior in research models indicates excessive synaptic plasticity in limbic circuits without corresponding adaptation in prefrontal regulatory pathways. Resume dosing after washout at 50% of the prior dose and shift to an intermittent schedule. 3 days per week maximum. Daily administration without breaks creates cumulative neurological load that regulatory systems cannot compensate for. Intermittent dosing preserves cognitive enhancement effects while allowing synaptic pruning and homeostatic regulation between doses.

Use sequential administration with a 48-hour interval between peptides rather than concurrent dosing. Cartalax administered first (days 1, 3, 5) allows chondroprotective mechanisms to initiate before introducing immune modulation with Thymalin (days 2, 4, 6). This approach isolates each peptide's contribution to outcome measures and prevents confounding if adverse interactions occur. Chronic joint inflammation elevates systemic IL-6 and TNF-alpha, which suppress thymic function. Addressing the inflammatory source with Cartalax before introducing Thymalin creates a more permissive environment for immune restoration.

Prepare both compounds at identical molar concentrations and administer at equimolar doses adjusted for molecular weight differences. The acetyl modification adds approximately 42 Da to Selank's molecular weight (approximately 751 Da for Selank vs 793 Da for Selank Amidate), meaning 1 mg of Selank Amidate contains fewer moles than 1 mg of standard Selank. Dosing both at

Evaluate whether the hyperactivity represents maladaptive dysregulation or adaptive increases in exploratory behavior. If the model shows functional cognitive performance improvements alongside hyperactivity. Improved maze learning, novel object recognition, problem-solving. The behavior may reflect enhanced motivation rather than pathology. If hyperactivity is accompanied by stereotypy, repetitive behavior, or performance decrements, reduce dose by 30–40% and implement structured rest periods. Sleep architecture disruption typically normalizes by day 10–12 as circadian systems adapt; persistence beyond this window suggests dosing frequency is too high.

Order unreconstituted lyophilised powder in smallest available vial sizes (1–5 mg per vial) rather than bulk quantities, even if per-unit costs increase. Reconstitute only the volume needed for 7–10 days of experiments when working with Thymalin. The 14-day stability window means bulk reconstitution wastes material. Cartalax's 28-day stability allows slightly larger reconstitution volumes, but the tetrapeptide's low molecular weight means 5 mg of powder yields 5,000 mcg of peptide. Sufficient for 25–100 doses depending on protocol. Divide bulk powder shipments into working aliquots immediately upon receipt and store at −80°C to minimize freeze-thaw cycles.

Discontinue dihexa administration immediately and retest ALT/AST levels 7–10 days post-cessation. Elevations documented in research models are mild (1.5–2.5× baseline) and fully reversible. If enzyme markers return to baseline within 14 days, the elevation was metabolic adaptation, not hepatotoxicity. Future protocols in the same model should use doses no higher than 8mg/kg and should not exceed 21 consecutive days without a 14-day washout. If enzyme markers do not normalize within 14 days, histological examination of liver tissue is warranted to rule out unrelated pathology.

Do not use it. Cloudiness indicates incomplete dissolution, peptide aggregation, or contamination. Gently swirl the vial again for 2–3 minutes. If it clears completely, it's likely fine. If cloudiness persists or you see floating particles, the peptide has degraded or the vial is contaminated. Particulate matter in injectable solutions creates embolism risk in vivo models and invalidates sterility requirements for research protocols.

Reconstitute a new vial every 28 days to stay within the bacteriostatic water effectiveness window. Calculate total peptide needed for 30 days, divide by 28-day segments, and order accordingly. For example, 500mcg daily dosing for 30 days requires 15mg total. One 10mg vial covers 20 days, so you'll need two vials. Reconstitute the second vial on day 22 to ensure no gap in your protocol while staying within the 28-day use window.

Verify neurosteroid synthesis capacity is intact in your model. If 5α-reductase is already saturated or pregnenolone metabolism is blocked downstream, PE-22-28 can't compensate. Measure hippocampal allopregnanolone concentrations via LC-MS before and after PE-22-28 administration; if levels don't increase, the issue is metabolic blockade, not peptide inactivity. Consider combining PE-22-28 with dutasteride or finasteride withdrawal if prior 5α-reductase inhibition is present, or confirm that your model exhibits StAR downregulation (chronic unpredictable stress, chronic corticosterone) rather than acute receptor desensitization.

Verify three factors: peptide purity and sequence accuracy (request CoA), reconstitution concentration calculations, and dosing administration route. Published PE-22-28 research uses specific dosing ranges and administration methods—subcutaneous injection produces different pharmacokinetics than intraperitoneal. Additionally, confirm your animal model matches the species and strain used in the reference study; neuroinflammatory responses vary significantly across rodent strains. If all protocol variables align but results still differ, peptide degradation during storage or handling is the most likely cause.

Co-administration is theoretically feasible since melatonin vs Pinealon operate through non-overlapping mechanisms. Melatonin via MT receptor pathways and Pinealon via gene modulation. No direct pharmacokinetic interaction has been documented in published studies. However, researchers must design dual-endpoint protocols carefully: polysomnography for melatonin's circadian effects measured within 2–4 weeks, and cognitive or neuroimaging assessments for Pinealon's neuroprotective effects measured over 3–6 months. The challenge is temporal. Melatonin effects manifest acutely while Pinealon requires chronic cycles, making concurrent short-term studies methodologically complex.

Aggregation indicates either incorrect reconstitution solvent, excessive agitation, or freeze-thaw cycles. Reconstitute PE-22-28 with sterile water or bacteriostatic water only. Never use saline or buffered solutions unless specified by the supplier, as ionic strength can destabilize the peptide backbone. Add solvent slowly down the vial wall rather than directly onto the lyophilized pellet, and allow passive dissolution for 5–10 minutes without vortexing. Once reconstituted, aliquot into single-use volumes and store at −80°C; each aliquot should be thawed once and discarded after use. Aggregated peptide shows reduced bioactivity in mitochondrial transport assays and should not be used.

Cloudiness indicates peptide aggregation or contamination—either scenario renders the solution unsuitable for research use. Proper reconstitution with bacteriostatic water should produce a clear, colorless solution. Aggregation occurs when lyophilization was performed improperly or when the peptide was frozen post-reconstitution. Contamination suggests non-sterile reconstitution technique or compromised bacteriostatic water. Do not attempt to filter or clarify the solution; discard it and reconstitute a fresh vial using strict aseptic technique.

Discard it and order a replacement. Lyophilised peptides experience measurable degradation at room temperature, with tripeptides showing 12–18% purity loss after one week at 25°C. A 48-hour excursion likely caused 3–6% degradation. Not enough to render it completely inactive, but enough to compromise research validity. Research outcomes depend on consistent dosing, and using a partially degraded vial introduces an uncontrolled variable that invalidates your protocol.

PE-22-28's 28-amino acid sequence makes it susceptible to proteolytic degradation in the GI tract, and bioavailability via oral administration is negligible without modification. Intranasal delivery bypasses first-pass metabolism and achieves CNS penetration via olfactory and trigeminal pathways, but requires formulation with permeation enhancers (chitosan, cyclodextrins) to cross the nasal epithelium effectively. If subcutaneous injection isn't feasible, intranasal delivery at 2–3× the subcutaneous dose is the next-best route, though pharmacokinetic validation in your specific model is required. Oral delivery is not viable for unmodified PE-22-28 and should be avoided unless using a PEGylated or lipid-encapsulated analog.